Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3088464 24 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Autoantibodies to exocrine-pancreatic glycoprotein 2 (anti-GP2) are Crohn's disease (CD) markers. However, CD-specific antibodies have also been found in celiac-disease (CeD) patients, in which type 1 diabetes-specific autoantibodies against endocrine pancreatic targets can be present. We investigated whether anti-GP2 are also present in CeD, a disease like CD which is also characterised by intestinal mucosal inflammation with barrier impairment. Methods: Antibodies against GP2, tissue transglutaminase (tTG), deamidated gliadin (dGD), glutamic decarboxylase (GAD), and islet antigen-2 (IA2) were tested in sera from 73 CD patients, 90 blood donors (BD), and 79 (58 de novo) CeD patients (2 consecutive sera were available from 40 patients). Results: IgA and/or IgG anti-GP2 were found in 15/79 (19.0%) CeD patients on at least one occasion, in 25/73 (34.2%) CD patients, and in 4/90 (4.4%) BD (CeD vs. CD, p=0.042; BD vs. CeD and CD, p<0.001, respectively). Amongst the 58 de novo CeD patients, anti-GP2 IgA and/or IgG were present in 11 (19.0%). Anti-GP2 IgA was significantly less prevalent in CeD compared with CD (p=0.004). Anti-GP2 IgA and IgG in CD patients demonstrated a significantly higher median level compared to patients with CeD (p<0.001, p=0.008, respectively). IgA anti-GP2 levels correlated significantly with IgA anti-tTG and anti-dGD levels in CeD Spearman's coefficient of rank correlation (ρ)=0.42, confidence interval (CI): 0.26-0.56, p<0.001; ρ=0.54, CI 0.39-0.65, p<0.001, respectively. Conclusions: The presence of anti-GP2 in CeD patients supports the notion that loss of tolerance to GP2 can probably be a manifestation of an autoinflammatory process in this intestinal disorder. © 2015 by De Gruyter.
Έτος δημοσίευσης:
2015
Συγγραφείς:
Roggenbuck, D.
Vermeire, S.
Hoffman, I.
Reinhold, D.
Schierack, P.
Goihl, A.
Von Arnim, U.
De Hertogh, G.
Polymeros, D.
Bogdanos, D.P.
Bossuyt, X.
Περιοδικό:
Clinical Chemistry and Laboratory Medicine (CCLM)
Εκδότης:
Walter de Gruyter GmbH
Τόμος:
53
Αριθμός / τεύχος:
9
Σελίδες:
1349-1357
Λέξεις-κλειδιά:
autoantibody; bispecific antibody; gliadin antibody; glutamate decarboxylase; glycoprotein 2 antibody; immunoglobulin A antibody; immunoglobulin G antibody; protein antibody; protein glutamine gamma glutamyltransferase antibody; unclassified drug; autoantibody; glycosylphosphatidylinositol anchored protein; GP2 protein, human; immunoglobulin A; immunoglobulin G, adolescent; adult; antibody blood level; Article; blood donor; celiac disease; child; comparative study; Crohn disease; enzyme linked immunosorbent assay; female; human; immunological tolerance; major clinical study; male; priority journal; blood; case control study; celiac disease; cohort analysis; Crohn disease; follow up; immunology; insulin dependent diabetes mellitus; time factor; young adult, Adolescent; Adult; Autoantibodies; Case-Control Studies; Celiac Disease; Child; Cohort Studies; Crohn Disease; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; GPI-Linked Proteins; Humans; Immunoglobulin A; Immunoglobulin G; Male; Time Factors; Young Adult
Επίσημο URL (Εκδότης):
DOI:
10.1515/cclm-2014-0238
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.